Related Experiment Video
Updated: Dec 31, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[Prevention and Treatment of Cancer Therapeutics-related Cardiac Dysfunction]
1Department of Medical Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Abstract:
Cancer therapeutics-related cardiac dysfunction(CTRCD)is receiving more attention.Risk factors assessment before cancer therapy,cardiac function monitoring during and after cancer therapy,and early detection and treatment of myocardial injury are key to preventing clinical heart failure.The incidence and severity of cardiotoxicity can be reduced by measures such as reducing drug dose,adjusting administration route,and using low toxic drugs.Cardioprotective agents including anti-heart failure drugs and dexrazoxane are important for the prevention and treatment of CTRCD.Patients with advanced heart failure may also benefit from mechanical treatments including cardiac resynchronization therapy and mechanically-assisted ventricular devices.This article reviews the recent advances in the prevention and treatment of CTRCD.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Coronary Artery Disease V: Interprofessional Care
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

